Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the upcoming 43rd annual Canaccord Genuity Growth Conference. The conference is slated for Aug. 7–10, 2023. According to the announcement, Cybin CEO Doug Drysdale will participate in a live … Continue reading InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference